Skip to content
OpenCapital
Get started

Pfizer PFE Lorbrena — Revenues:

Other product segments

Eliquis
$2.17B+12.6%
Prevnar Family
$1.69B+1.8%
Vyndaqel family
$1.6B+7.8%
Ibrance
$1.01B+3.2%
All Other Hospital and Biosimilars
$953M—
All other Primary Care
$654M+7.4%
Padcev
$591M+38.7%
All other Specialty Care
$579M+19.1%
Xtandi
$444M-3.1%
Oncology Biosimilars
$409M+54.9%
Royalty
$396M+28.6%
All other Oncology
$376M-0.3%
Nurtec ODT/Vydura
$353M+42.3%
Pfizer CentreOne
$289M+5.9%
Comirnaty
$232M-58.9%
Paxlovid
$219M-69.9%
Inlyta
$214M-2.3%
Sulperazon (Outside the U.S. and Canada)
$199M+21.3%
Adcetris
$190M-12.8%
Inflectra
$182M—
Abrysvo
$180M+37.4%
Xeljanz
$180M+40.6%
Braftovi/Mektovi
$174M+27.9%
Zavicefta (Outside the U.S. and Canada)
$150M+11.1%
Enbrel (Outside the U.S. and Canada)
$138M-1.4%
Bosulif
$129M-14.6%
Octagam
$122M—
Tukysa
$122M+19.6%
Zithromax
$112M-29.1%
Orgovyx
$109M—
Genotropin
$93M—
FSME-IMMUN/TicoVac
$81M—
Elrexfio
$80M+33.3%
Cibinqo
$76M+31.0%
Talzenna
$50M+25.0%
Tivdak
$33M0.0%

Similar metrics at other companies

TransMedics Group, Inc. logo
TMDXLung Product — Revenue
$2.82M-29.6%
Eli Lilly logo
LLYOncology — Revenue
$2.27B+16.4%
Schrodinger logo
SDGROncology, Neurology, and Immunology Product — Total revenues
$700K+16.7%
BillionToOne, Inc. logo
BLLNOncology — Revenue
$10.72M+392%
RFL
RFLProduct Revenue — Revenue
$89K-63.4%
Eli Lilly logo
LLYOther oncology — Revenue
$966M+22.4%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$138.21B-3.7%
Enterprise value$200.88B-1.3%
P/E11.4×—
P/S2.2×-0.1×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's lorbrena — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's lorbrena — revenues:?
Pfizer (PFE) reported lorbrena — revenues: of $305M in Q1 2026.
How has Pfizer's lorbrena — revenues: changed year-over-year?
Pfizer's lorbrena — revenues: increased by 37.4% year-over-year, from $222M to $305M.
What is the long-term trend for Pfizer's lorbrena — revenues:?
Over 4 years (2021 to 2025), Pfizer's lorbrena — revenues: has grown at a 40.0% compound annual growth rate (CAGR), from $266M to $1.02B.
What does lorbrena — revenues: mean?
This metric represents the total gross sales generated by a specific oncology pharmaceutical product line within the company's portfolio. It reflects the market adoption, pricing power, and therapeutic demand for this targeted therapy in the treatment of non-small cell lung cancer. Tracking this revenue stream provides insight into the commercial success of the company's precision medicine strategy and its ability to capture market share in competitive oncology segments.